Health research cooperation between China and the United States has expanded significantly in recent years, bringing new momentum to global medical and scientific innovation.
According to a November report by the Quincy Institute for Responsible Statecraft, the number of jointly authored health-related scientific papers by Chinese and American researchers has increased substantially over the past decade.
The report noted that collaborative research in genetic association and epidemiology rose by 77.78 percent. Studies related to liver disease diagnosis and treatment increased by 55.56 percent, while research on single-cell and spatial transcriptomics grew by 38.95 percent.
One recent example of cooperation involves anti-aging medicine research. Scientists from Sinopharm affiliate Sinopharm Seragon, Tsinghua University, and US-based Seragon jointly published pre-clinical findings on a new longevity drug known as SRN-901.
According to the research, the drug increased the average lifespan of mice by nearly one-third and slowed the aging process by around 70 percent. Researchers also observed a 30.53 percent reduction in tumor formation and a 46 percent decrease in overall mortality risk. External signs of rejuvenation, including improvements in skin, fur, and muscle condition, were also reported.
At the molecular level, the drug reportedly activates beneficial pathways associated with DNA repair, mitochondrial autophagy, and cellular autophagy, while suppressing inflammation and aging-related cellular degeneration.
Health-sector cooperation between the two countries has also expanded through academic conferences and training exchanges.
In March 2026, a cancer prevention and treatment conference was held in Guangzhou, jointly organized by the First Affiliated Hospital of Sun Yat-sen University and the Dana-Farber Cancer Institute.
Officials from the Dana-Farber Cancer Institute said they are currently working closely with Chinese institutions on research involving lung, colorectal, and breast cancers.
